Maravai LifeSciences Sees Unusually High Options Volume (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) was the target of unusually large options trading on Wednesday. Stock investors purchased 1,002 put options on the company. This represents an increase of approximately 1,791% compared to the average daily volume of 53 put options.

Insiders Place Their Bets

In related news, insider Carl Hull acquired 175,000 shares of Maravai LifeSciences stock in a transaction dated Monday, November 11th. The shares were purchased at an average price of $5.64 per share, for a total transaction of $987,000.00. Following the completion of the transaction, the insider now directly owns 175,000 shares in the company, valued at approximately $987,000. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.63% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Maravai LifeSciences during the second quarter valued at approximately $32,000. Venturi Wealth Management LLC bought a new position in Maravai LifeSciences in the 3rd quarter valued at $47,000. Custom Index Systems LLC bought a new position in Maravai LifeSciences in the 3rd quarter valued at $97,000. Y Intercept Hong Kong Ltd purchased a new stake in Maravai LifeSciences in the third quarter worth $105,000. Finally, Headlands Technologies LLC lifted its position in shares of Maravai LifeSciences by 205.9% during the second quarter. Headlands Technologies LLC now owns 14,935 shares of the company's stock worth $107,000 after purchasing an additional 10,053 shares during the last quarter. 50.25% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently weighed in on MRVI shares. Royal Bank of Canada cut their target price on shares of Maravai LifeSciences from $17.00 to $13.00 and set an "outperform" rating for the company in a research note on Friday, November 8th. Wolfe Research initiated coverage on Maravai LifeSciences in a report on Thursday, November 14th. They issued a "peer perform" rating on the stock. The Goldman Sachs Group downgraded Maravai LifeSciences from a "neutral" rating to a "sell" rating and decreased their target price for the stock from $7.00 to $4.25 in a research report on Thursday, December 5th. Guggenheim began coverage on Maravai LifeSciences in a report on Thursday, December 19th. They set a "neutral" rating for the company. Finally, William Blair reaffirmed a "market perform" rating on shares of Maravai LifeSciences in a report on Friday, November 8th. One research analyst has rated the stock with a sell rating, five have given a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $10.28.

Maravai LifeSciences Trading Up 5.3 %

Shares of Maravai LifeSciences stock traded up $0.28 on Thursday, reaching $5.61. The company had a trading volume of 1,485,756 shares, compared to its average volume of 2,209,385. The firm's 50-day moving average price is $6.07 and its two-hundred day moving average price is $7.54. Maravai LifeSciences has a 1 year low of $4.28 and a 1 year high of $11.56. The firm has a market cap of $1.42 billion, a price-to-earnings ratio of -3.42 and a beta of -0.07. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.